Igor Gosev1, Michael S Kiernan2, Peter Eckman3, Behzad Soleimani4, Ahmet Kilic5, Nir Uriel6, Jonathan D Rich7, Jason N Katz8, Jennifer Cowger9, Brian Lima10, Siobhan McGurk11, Meredith A Brisco-Bacik12, Sanjin Lee13, Susan M Joseph14, Chetan B Patel15. 1. Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: igorgosev@gmail.com. 2. Department of Medicine, Tufts Medical Center, Boston, Massachusetts. 3. Minneapolis Heart Institute, Minneapolis, Minnesota. 4. Department of Surgery, Penn State Hershey Heart and Vascular Institute, Hershey, Pennsylvania. 5. Department of Surgery, Wexner Medical Center, Columbus, Ohio. 6. Deparmtent of Medicine, University of Chicago Medicine, Chicago, Illinois. 7. Department of Medicine, Northwestern Memorial Hospital, Chicago, Illinois. 8. Department of Medicine, University of North Carolina Hospital, Chapel Hill, North Carolina. 9. Department of Medicine, St. Vincent Hospital, Indianapolis, Indiana. 10. Department of Surgery, Baylor University Medical Center, Dallas, Texas. 11. Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts. 12. Temple University, Philadelphia, Pennsylvania. 13. Spectrum Health Systems, Grand Rapids, Michigan. 14. Department of Medicine, Barnes-Jewish Hospital, St. Louis, Missouri. 15. Department of Medicine, University Medical Center, Durham, North Carolina.
Abstract
BACKGROUND: Long-term survivors after implantation of left ventricular assist devices (LVADs) are increasing in prevalence. We describe the characteristics and outcomes in patients surviving longer than 4 years on LVAD support. METHODS: We performed a multicenter, retrospective analysis of patients surviving at least 4 years on continuous-flow LVAD (CF-LVAD) support with a HeartMate II at centers participating in the Evolving Mechanical support Research Group. RESULTS: Between 2005 and 2010, 156 long-term survivors were identified with a mean survival of 7.1 years (95% confidence interval: 6.7 to 7.5 years). The mean age was 58.2 ± 15.2 years and 30.1% were women. Readmission rate was low at 1.1 events per patient per year with the most common reasons leading to readmission being infection (0.10 readmissions per patient per year) and gastrointestinal bleeding (0.07 readmissions per patient per year). Two years after implantation, 97% of patients were either New York Heart Association functional class I or II, with 92% at 4 years. CONCLUSIONS: Patients surviving 4 years on CF-LVAD support can anticipate ongoing long-term survival with sustained improvements in functionality and low rates of rehospitalization.
BACKGROUND: Long-term survivors after implantation of left ventricular assist devices (LVADs) are increasing in prevalence. We describe the characteristics and outcomes in patients surviving longer than 4 years on LVAD support. METHODS: We performed a multicenter, retrospective analysis of patients surviving at least 4 years on continuous-flow LVAD (CF-LVAD) support with a HeartMate II at centers participating in the Evolving Mechanical support Research Group. RESULTS: Between 2005 and 2010, 156 long-term survivors were identified with a mean survival of 7.1 years (95% confidence interval: 6.7 to 7.5 years). The mean age was 58.2 ± 15.2 years and 30.1% were women. Readmission rate was low at 1.1 events per patient per year with the most common reasons leading to readmission being infection (0.10 readmissions per patient per year) and gastrointestinal bleeding (0.07 readmissions per patient per year). Two years after implantation, 97% of patients were either New York Heart Association functional class I or II, with 92% at 4 years. CONCLUSIONS:Patients surviving 4 years on CF-LVAD support can anticipate ongoing long-term survival with sustained improvements in functionality and low rates of rehospitalization.
Authors: Richard Severin; Ahmad Sabbahi; Cemal Ozemek; Shane Phillips; Ross Arena Journal: Expert Rev Med Devices Date: 2019-09-06 Impact factor: 3.166
Authors: Zerelda Esquer Garrigos; Natalia E Castillo Almeida; Pooja Gurram; Prakhar Vijayvargiya; Cristina G Corsini Campioli; John M Stulak; Stacey A Rizza; Larry M Baddour; M Rizwan Sohail Journal: Open Forum Infect Dis Date: 2020-07-20 Impact factor: 3.835
Authors: Anuradha Lala; John C Rowland; Bart S Ferket; Annetine C Gelijns; Emilia Bagiella; Sean P Pinney; Alan J Moskowitz; Marissa A Miller; Francis D Pagani; Donna M Mancini Journal: JAMA Cardiol Date: 2020-06-01 Impact factor: 14.676
Authors: Katherine C Michelis; Lin Zhong; Matthias Peltz; Ambarish Pandey; W H Wilson Tang; Anand Rohatgi; James B Young; Mark H Drazner; Justin L Grodin Journal: J Am Heart Assoc Date: 2020-07-10 Impact factor: 5.501
Authors: Christopher Wavell; Andrew Sokolowski; Michelle L Klingel; Charles Yin; A Dave Nagpal Journal: Can J Surg Date: 2021-01-26 Impact factor: 2.089
Authors: Melissa A Austin; Abhiraj Saxena; Thomas J O'Malley; Elizabeth J Maynes; Henry Moncure; Nathan Ott; H Todd Massey; Francesco Moscato; Antonio Loforte; John M Stulak; Vakhtang Tchantchaleishvili Journal: Ann Cardiothorac Surg Date: 2021-05